To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
← catalyst calendarSponsored by Neumora Therapeutics, Inc. (industry) · NMRA — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
18actual
Sites
21
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-13 | actual | When the study began enrolling |
| Primary completion | 2025-04-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-30 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Major Depressive Episode Associated With Bipolar II Disorder
Interventions
- Drug: NMRA-335140 80 mg — also filed as BTRX-335140, CYM-53093, Navacaprant
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score
measured Baseline and up to Week 6
Permalink · NMRA's whole pipeline · Catalyst calendar · Every registered study · What changed